) The SPORE DRP in Ovarian Cancer will provide funding for pilot translational research studies in ovarian cancer. The program will emphasize support of translational research projects that can generate clinically testable hypotheses with potential for reducing ovarian cancer incidence or mortality, or improving survival and quality of life of ovarian cancer patients. Proposals of no more than 5 pages for innovative translational research will be solicited by the SPORE Administrative Core from all institutional investigators, including participants in the SPORE CDP. The Administrative Core will work with the investigators submitting proposals to help them formulate the translational specific aims and research plan since many of these investigators will not have experience or expertise in this new area. This process will also serve as a major educational function and further stimulate innovative translational research concepts. Competing proposals will be screened by the Executive Committee using objective criteria. Investigators of selected proposals will then prepare a 10-page proposal modeled after an NIH RO1 submission. These proposals will then be forwarded to members of the External Scientific Advisory Committee for prioritization. The SPORE Executive Committee will then meet to make the final selection of research projects. Projects will be funded for one year and will be renewable for one additional year. Promising projects will be renewed and/or recommended for seeking other peer reviewed support; others will be terminated after the initial funding period. This entire process will be the responsibility of the Administrative Core led by the SPORE Co-Principal Investigator and Principal Investigator, who will work on a continuous basis to facilitate success by assisting investigators to either progress to full projects or to obtain other funding. These leaders will be assisted by the Executive Committee in all aspects of this process. Presented herein are six examples of Developmental Projects that represent the spectrum of projects that will compete for SPORE DRP funding. In each case, they relate to ovarian cancer, utilize multidisciplinary talent present at MDACC, are translational in nature, have the potential to integrate with one or more of the full projects, and will use the SPORE Core resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083639-04
Application #
6665648
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-27
Project End
2003-08-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Haemmerle, Monika; Stone, Rebecca L; Menter, David G et al. (2018) The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33:965-983
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826
Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210
Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15

Showing the most recent 10 out of 648 publications